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very low costs or even no medical attention, and therefore were not taken into account. 
Data sources included the published incidence rates for the 25 most frequent AE in 
controlled clinical trials with BEV + IFN or sunitinib. a panel integrated by 10 local 
experts from different specialties was constituted to estimate medical and nonmedical 
resource use for diagnosis and treatment of each AE grade 3/4. Cost of medications 
involved in treating AE were taken from public bids and unit cost of medical services 
(outpatient medical consultations, laboratory and image tests, hospitalization at 
general ward and at intensive care unit, surgical and nonsurgical procedures, etc.) was 
gathered from ofﬁ cial tariff lists. All costs are expressed in 2009 Mexican pesos 
(MXN). RESULTS: The average cost per patient for the management of grade 3/4 AE 
were 76.5% higher for sunitinib ($17,577) than those for BEV + IFN ($9959). The 
main cost drivers for sunitinib were hypertension, heart failure, and non-febrile neu-
tropenia; for BEV + IFN, main cost drivers included proteinuria and arterial and 
venous thromboembolic events. CONCLUSIONS: BEV + IFN has a more tolerable 
AE proﬁ le when compared to sunitinib, which is also reﬂ ected in the nearly double 
cost for managing AE with sunitinib in patients with mRCC.
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OBJECTIVES: First-line chemotherapy for locally advanced or metastatic non-small 
cell lung cancer (mNSCLC) is usually limited to four to six cycles, as prolonged 
exposure leads to cumulative toxicity without additional survival beneﬁ t. Maintenance 
therapy represents a new treatment option which can delay disease progression and 
extend survival in patients with mNSCLC. Erlotinib and pemetrexed are currently the 
only treatments speciﬁ cally approved for this indication by the European Medicines 
Agency and US Food and Drug Administration; therefore, it is important to compare 
the monthly treatment costs of using erlotinib or pemetrexed for the maintenance 
therapy of patients with mNSCLC. METHODS: Italian monthly treatment costs were 
calculated as the sum of the ex-factory costs for the average dose (erlotinib = 150 mg/
day, pemetrexed = 500 mg/m2) over a 30-day treatment duration plus administration 
costs. Monthly administration costs were derived from regional tariffs for oncology 
drugs. RESULTS: Monthly drug costs for erlotinib maintenance therapy are lower 
than for pemetrexed (c1517 vs. c2770, respectively). In addition, as an intravenous 
treatment, pemetrexed is associated with additional costs related to administration 
(estimated at c140 per month), whereas orally administered erlotinib is not associated 
with any administration costs. Pemetrexed total monthly treatment costs are therefore 
c2910, c1393 higher than erlotinib total monthly treatment costs. The cost saving 
associated with erlotinib would allow approximately 92% more patients to be treated 
with erlotinib maintenance therapy, based on a ﬁ xed health-care budget. Furthermore, 
it is anticipated that the management of pemetrexed-related adverse events (e.g., 
neutropenia, anaemia) would be more costly than those related to erlotinib use (e.g., 
rash, pruritus). Therefore, the cost saving when using erlotinib versus pemetrexed for 
ﬁ rst-line maintenance therapy may be greater in a real-world setting. CONCLU-
SIONS: Based on Italian costs, erlotinib is a cost-saving treatment option compared 
with pemetrexed, for the ﬁ rst-line maintenance therapy of patients with locally 
advanced or mNSCLC.
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OBJECTIVES: First-line chemotherapy for locally advanced or metastatic non-small 
cell lung cancer (mNSCLC) is usually limited to four to six cycles, as prolonged 
exposure leads to cumulative toxicity without additional survival beneﬁ t. Maintenance 
therapy represents a new treatment option which can delay disease progression and 
extend survival in patients with mNSCLC. Erlotinib and pemetrexed are currently the 
only treatments speciﬁ cally approved for this indication by the European Medicines 
Agency and US Food and Drug Administration; therefore, it is important to compare 
the monthly treatment costs of using erlotinib or pemetrexed for the maintenance 
therapy of patients with mNSCLC. METHODS: Spanish monthly treatment costs 
were calculated as the sum of the ex-factory costs for the average dose (erlotinib = 
150 mg/day, pemetrexed = 500 mg/m2) over a 30-day treatment duration plus admin-
istration costs. Monthly administration costs were obtained from regional tariffs 
(Galician Health Service). RESULTS: Monthly drug costs for erlotinib maintenance 
therapy are lower than for pemetrexed (c2045 vs. c2914, respectively). In addition, 
as an intravenous treatment, pemetrexed is associated with additional costs related to 
administration (estimated at c235 per month), whereas orally administered erlotinib 
is not associated with any administration costs. Pemetrexed total monthly treatment 
costs are therefore c3149, c1104 higher than erlotinib total monthly treatment costs. 
The cost saving associated with erlotinib would allow approximately 54% more 
patients to be treated with erlotinib maintenance therapy, based on a ﬁ xed health-care 
budget. Furthermore, it is anticipated that the management of pemetrexed-related 
adverse events (e.g., neutropenia, anaemia) would be more costly than those related 
to erlotinib use (e.g., rash, pruritus). Therefore, the cost saving when using erlotinib 
versus pemetrexed for ﬁ rst-line maintenance therapy may be greater in a real-world 
setting. CONCLUSIONS: Based on Spanish costs, erlotinib is a cost-saving treatment 
option compared with pemetrexed, for the ﬁ rst-line maintenance therapy of patients 
with locally advanced or mNSCLC.
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OBJECTIVES: Patients with CRPC may be treated by urologists or oncologists. This 
study examined differences in total health-care costs and prostate cancer-speciﬁ c costs 
in patients treated by oncologists or urologists. METHODS: A retrospective study 
design used medical and pharmacy claims (2001–2007) to identify patients with CRPC 
from a large US-managed care health plan. Patients were stratiﬁ ed based on the spe-
cialist providing treatment following castration; an oncologist (with/without a urolo-
gist, ONC), and a urologist without an oncologist (URO). A 6-month baseline period 
was used to assess patient characteristics and initial clinical status; a variable follow-up 
period (until disenrollment or December 31, 2008) was used to assess total health-care 
costs. Lin’s regression was used to assess costs adjusting for the variable follow-up 
and patient and treatment characteristics. RESULTS: A total of 995 URO and 1590 
ONC patients with CRPC were identiﬁ ed. Mean age was higher in URO patients than 
in ONC patients (75.5 vs. 71.1 years, P < 0.001). The URO cohort had a lower average 
Charlson comorbidity score (3.7 vs. 4.9, P < 0.001), fewer comorbid illnesses (10.1 vs. 
11.1, P < 0.001), and were less likely to have other cancers (17.7% vs. 27.4%, P < 
0.001) or to have had hormones, chemotherapy, and radiation treatment during the 
baseline period. After multivariate adjustment, mean total health-care costs during the 
ﬁ rst year were $31,792 (URO), $54,306 (ONC with chemotherapy, P < 0.05), and 
$30,894 (ONC without chemotherapy); during 6 years of follow-up, cumulative costs 
rose to $86,706 (URO), $168,794 (ONC with chemotherapy), and $114,180 (ONC 
without chemotherapy), P < 0.05 for all. a similar pattern was observed for prostate 
cancer-speciﬁ c cumulative costs. CONCLUSIONS: CRPC patients treated by oncolo-
gists, particularly patients with chemotherapy, had higher total and prostate cancer-
related health-care costs than patients treated by urologists.
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OBJECTIVES: Oncotype DX® is a clinically validated assay used to guide chemo-
therapy decision-making for patients with early-stage breast cancer. Patients classiﬁ ed 
as low risk by Oncotype DX® have low likelihood of beneﬁ tting from chemotherapy. 
By foregoing chemotherapy, patients avoid the risk of chemotherapy-related toxicities. 
For those patients reclassiﬁ ed by Oncotype DX® as high risk, the assay identiﬁ es 
patients who are likely to gain a large beneﬁ t from chemotherapy. The study objective 
was to estimate the health-care costs of using Oncotype DX® testing in early-stage, 
lymph node-negative breast cancer in Ireland. METHODS: A cost-analysis estimated 
the health-care costs (chemotherapy, administration, adverse events [AEs], and G-CSF 
costs) in patients whose treatment decisions are informed by Oncotype DX® testing. 
The perspective was that of the Irish health-care system. The chemotherapy regimen 
was docetaxel and cyclophosphamide (4 × 21-day cycles), costing approximately 
c9200. Univariate sensitivity analysis was performed, together with a probabilistic 
sensitivity analysis (PSA) of the net reduction in chemotherapy usage from Oncotype 
DX® testing. In a meta-analysis of seven published studies, there was an estimated 
30% (95% CI −40%, −21%; P = 0.0003) absolute reduction in chemotherapy usage 
after Oncotype DX® testing (ratio 0.49 [95% CI 0.41, 0.58]; P < 0.00001). RESULTS: 
Adoption of Oncotype DX® testing resulted in approximate cost-neutrality (0.4% 
increase in cost) to the Irish health-care system, under the above conditions. The main 
cost drivers were: net reduction in chemotherapy usage from Oncotype DX® testing 
and the rate of G-CSF usage. From the PSA, the probability of Oncotype DX® being 
cost-saving is approximately 47%. CONCLUSIONS: Using Oncotype DX® to inform 
chemotherapy decisions in early-stage breast cancer has the potential to reduce the 
incidence of chemotherapy-induced AEs, while being approximately cost-neutral to 
the Irish health-care system. a cost-effectiveness analysis would be expected to result 
in a low incremental cost-effectiveness ratio.
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OBJECTIVES: To describe changes in outcomes, treatment patterns and costs of the 
management of hospitalized patients with acute AML after chemotherapy in Germany 
